Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Robert James Mayer, Eric Van Cutsem, Alfredo Falcone et al. · New England Journal of Medicine · 2015
BACKGROUND: Early clinical trials conducted primarily in Japan have shown that TAS-102, an oral agent that combines trifluridine and tipiracil hydrochloride, was effective in the treatment of refractory colorectal cancer. We conducted a phase 3 trial to further assess the efficacy and safety of TAS-102 in a global population of such patients. METHODS: In this double-blind study, we randomly assigned 800 patients, in a 2:1 ratio, to receive TAS-102 or placebo. The primary end point was overall survival. RESULTS: The median overall survival improved from 5.3 months with placebo to 7.1 months with TAS-102, and the hazard ratio for death in the TAS-102 group versus the placebo group was 0.68 (95% confidence interval [CI], 0.58 to 0.81; P<0.001). The most frequently observed clinically significant adverse events associated with TAS-102 were neutropenia, which occurred in 38% of those treated, and leukopenia, which occurred in 21%; 4% of the patients who received TAS-102 had febrile neutropenia, and one death related to TAS-102 was reported. The median time to worsening performance status (a change in Eastern Cooperative Oncology Group performance status [on a scale of 0 to 5, with 0 indicating no symptoms and higher numbers indicating increasing degrees of disability] from 0 or 1 to 2 or more) was 5.7 months with TAS-102 versus 4.0 months with placebo (hazard ratio, 0.66; 95% CI, 0.56 to 0.78; P<0.001). CONCLUSIONS: In patients with refractory colorectal cancer, TAS-102, as compared with placebo, was associated with a significant improvement in overall survival. (Funded by Taiho Oncology-Taiho Pharmaceutical; RECOURSE ClinicalTrials.gov number, NCT01607957.).
Cited by 1,422 works. doi:10.1056/nejmoa1414325 Open-access PDF
Authors
- Robert James Mayer
- Eric Van Cutsem
- Alfredo Falcone
- Takayuki Yoshino
- Rocio García‐Carbonero
- Nobuyuki Mizunuma
- Kentaro Yamazaki
- Yasuhiro Shimada
- Josep M. Tabernero
- Yoshito Komatsu
- Alberto Felice Sobrero
- Éveline Boucher
- Marc Peeters
- Ben Tran
- Heinz‐Josef Lenz
- Alberto Zaniboni
- Howard S. Höchster
- James M. Cleary
- Hans Prenen
- Fabio M. Benedetti
References
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- Systemic Therapy for Colorectal Cancer
- Systemic Therapy for Colorectal Cancer
- Use of Statins and the Risk of Death in Patients With Prostate Cancer
- Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial
- Structure and activity of specific inhibitors of thymidine phosphorylase to potentiate the function of antitumor 2′-deoxyribonucleosides
- The clinical pharmacology of 5-trifluoromethyl-2'-deoxyuridine.
- Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models
- Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours